Using 3D bioprinting to predict drug response in gastric cancer
Research on the Value of Predicting Drug Efficacy Based on 3D Bioprinting for Constructing In Vitro Gastric Cancer Models
This study is testing if 3D printed models of gastric cancer made from patient tissue can help predict how well chemotherapy will work for those patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06792149 on ClinicalTrials.gov |
What this trial studies
This observational study aims to create three-dimensional (3D) bioprinted models of gastric cancer using tumor tissues from patients who have undergone surgical resection. The 3D models will be treated with the same chemotherapy drugs that the patients receive, allowing researchers to assess the sensitivity of these drugs in vitro. By comparing the drug responses in the models with the actual patient outcomes, the study seeks to validate the effectiveness of 3D bioprinted tumor models in predicting chemotherapy responses for gastric cancer patients.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years old who have been diagnosed with gastric cancer and are scheduled for preoperative (neo)adjuvant therapy.
Not a fit: Patients with a history of other malignancies or serious medical conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized and effective chemotherapy treatments for gastric cancer patients.
How similar studies have performed: While the use of 3D bioprinting in cancer research is emerging, this specific approach to predict drug response in gastric cancer is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * More than 18 years old * Patients previously diagnosed with gastric cancer or confirmed by pathology as having gastric cancer postoperatively. * Patients who have undergone preoperative imaging examinations, including plain and contrast-enhanced CT scans of the chest, abdomen, and pelvis, as well as gastric MRI for tumor staging, and who are planned for preoperative (neo)adjuvant therapy after multidisciplinary team (MDT) discussion; patients with advanced gastric cancer who are confirmed by postoperative pathology to require (neo)adjuvant therapy. * The patient or their family members are able to comprehend the research protocol and are willing to participate in this study, providing written informed consent. Exclusion Criteria: * History of other malignancies or serious medical conditions * Inability to provide independent informed consent
Where this trial is running
Beijing, Beijing Municipality
- Peking Union Medical College Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Study coordinator: HuaYu Yang, PhD
- Email: dolphinyahy@163.com
- Phone: 8600-13911800460
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.